Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Prashni Paliwal"'
Autor:
Christy Osgood, Jiaxin Fan, Xin Gao, Catherine Keane, Jonathan Bryan, James P. Roose, Erik Bloomquist, Aracelis Torres, Shrujal Baxi, Nathan Nussbaum, Fatima Rizvi, Shenghui Tang, Irene Nunes, Julia Beaver, Donna R. Rivera, Lynn Howie, Prashni Paliwal, Laleh Amiri-Kordestani
Publikováno v:
Cancer Research. 83:P2-13
Objectives: Real-world data (RWD) from the clinical care of patients captured through Electronic Health Records (EHRs) is a valuable resource for research. Understanding the relationship between characteristics and outcomes of patients treated in the
Autor:
T.R. Jeffry Evans, Maurizio Voi, Shruti Agrawal, Prashni Paliwal, Valerie G. Brunton, Jeffrey A. Morgan, Ding Wang, Iain R.J. MacPherson, Patricia Lo Russo, George D. Demetri
Supplementary Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e06c2f09e172de59a9655afbe26c21e
https://doi.org/10.1158/1078-0432.22440253
https://doi.org/10.1158/1078-0432.22440253
Autor:
T.R. Jeffry Evans, Maurizio Voi, Shruti Agrawal, Prashni Paliwal, Valerie G. Brunton, Jeffrey A. Morgan, Ding Wang, Iain R.J. MacPherson, Patricia Lo Russo, George D. Demetri
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.Experimental Desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735eef4e2da338a45ef9202bee0418c9
https://doi.org/10.1158/1078-0432.c.6517603
https://doi.org/10.1158/1078-0432.c.6517603
Autor:
Laleh Amiri-Kordestani, Xin Gao, Shrujal Baxi, Erik Bloomquist, Jonathan Bryan, Lynn Howie, Catherine Keane, Paul G. Kluetz, Christy Osgood, Prashni Paliwal, Donna R. Rivera, James Roose, Julie Schneider, Harpreet Singh, Shenghui Tang, Lijun Zhang, Julia A. Beaver
Publikováno v:
Cancer Research. 82:P2-11
Objectives: Real-world data (RWD) from the routine care of patients with cancer captured through EHRs is a valuable resource for research. Understanding the relationship between characteristics and outcomes of patients treated in the real world and t
Autor:
Shrujal S. Baxi, Donna Rivera, Benjamin Ackerman, Catherine Keane, Laleh Amiri-Kordestani, Paul G. Kluetz, Prashni Paliwal, Philani Mpofu, Julia A. Beaver, Harpreet Singh
Publikováno v:
Journal of Clinical Oncology. 39:227-227
227 Background: Recent studies have demonstrated a decline in cancer screening and diagnosis during the COVID-19 pandemic. This study explored trends in the diagnosis and management of eBC at a sample of cancer clinics across the US early on in the p
Autor:
Michael Lim, Shakti Ramkissoon, Ricardo Zwirtes, Antonio Omuro, Robert Latek, Gordana Vlahovic, Timothy F. Cloughesy, Lewis C. Strauss, Joachim M. Baehring, Keith L. Ligon, Solmaz Sahebjam, Prashni Paliwal, David A. Reardon, Christopher T. Harbison, John H. Sampson, Alfredo Voloschin
Publikováno v:
Neuro-Oncology. 20:674-686
Background Immunotherapies have demonstrated efficacy across a diverse set of tumors supporting further evaluation in glioblastoma. The objective of this study was to evaluate the safety/tolerability and describe immune-mediated effects of nivolumab
Autor:
Satyendra Suryawanshi, Amit Roy, Michael Lim, Prashni Paliwal, Ricardo Zwirtes, Matthew Hruska, J. Shen, Von Potter, Akintunde Bello
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12162be6a6514f1c656f3236e3bc246
https://europepmc.org/articles/PMC5692350/
https://europepmc.org/articles/PMC5692350/
Autor:
Christopher J. Logothetis, Andrew J. Armstrong, Mathew Lonberg, Paul Mathew, Gary E. Gallick, Edwin M. Posadas, John C. Araujo, E. L. Braud, Prashni Paliwal, Shruti Agrawal, Geralyn C. Trudel
Publikováno v:
Cancer. 118:63-71
BACKGROUND: To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC
Autor:
Geralyn C. Trudel, Gary R. Hudes, Michael A. Carducci, Stéphane Culine, Prashni Paliwal, Evan Y. Yu, Christophe Massard, Edwin M. Posadas, Mitchell E. Gross, Karim Fizazi, Cora N. Sternberg, George Wilding
Publikováno v:
Urology. 77:1166-1171
Objectives To determine the activity and tolerability of 100-mg once-daily (QD) dasatinib in patients with metastatic castration-resistance prostate cancer (CRPC). Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and
Autor:
Iain R. Macpherson, Patricia Lo Russo, T.R. Jeffry Evans, George D. Demetri, Prashni Paliwal, Shruti Agrawal, Valerie G. Brunton, Jeffrey A. Morgan, Maurizio Voi, Ding Wang
Publikováno v:
Clinical Cancer Research. 15:6232-6240
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists. Experimental Des